Contact Us

News & Events

Lutetium(177) – Chloride n.c.a
29th September, 2025
Lutetium(177) – Chloride n.c.a
Lutetium(Lu177) – Eclipse (n.c.a ready labeled)
19th September, 2025
Lutetium(Lu177) – Eclipse (n.c.a ready labeled)
Lutetium(177) chloride n.c.a – Precursor solution
19th September, 2025
Lutetium(177) chloride n.c.a – Precursor solution
Lutetium(177) – Chloride n.c.a
29th September, 2025
Lutetium(177) – Chloride n.c.a

Lutetium-177 (Lu-177), branded as Ilumira by SHINE Technologies, is a non-carrier-added (n.c.a.) medical radioisotope used in targeted cancer therapies, particularly for treating advanced cancers like prostate and neuroendocrine tumors.
Lutetium(Lu177) – Eclipse (n.c.a ready labeled)
19th September, 2025
Lutetium(Lu177) – Eclipse (n.c.a ready labeled)

Ready Label Lu-177 from Curium is a non-carrier-added Lutetium-177 (n.c.a. Lu-177) radiopharmaceutical precursor used in targeted radionuclide therapy for cancer treatment. It is produced at Curium’s facility inFinland
Lutetium(177) chloride n.c.a – Precursor solution
19th September, 2025
Lutetium(177) chloride n.c.a – Precursor solution

Lutetium-177 (Lu-177), branded as Ilumira by SHINE Technologies, is a non-carrier-added (n.c.a.) medical radioisotope used in targeted cancer therapies, particularly for treating advanced cancers like prostate and neuroendocrine tumors.